We have seen major advances in the diagnosis and treatment of cancer but the questions remain: why do some treatments work on some people and not others? Why are the survival rates of some cancers still so low? And how can we prevent the estimated 22 million cancer cases that will be diagnosed annually worldwide within 20 years?
UniSA researchers and postgraduate students are working on many fronts to find the answers.
Our University’s ability to combine wide-ranging expertise across many disciplines helps us deliver innovative breakthroughs using a combination of new science, new techniques and new technologies.
With over 250 researchers working within the Centre for Cancer Biology, the Sansom Institute and throughout the University’s Mawson Lakes, City West and City East campuses, UniSA hosts the largest cohort of cancer researchers in South Australia. Many breakthroughs that are part of today’s treatments have been informed or designed by these researchers.
Your support of UniSA cancer research enables local researchers to make a global impact - one that will also directly help you and your family.
UniSA researchers believe the study of genes and their function can help discover why some individuals get cancer and some don't, and why some respond to treatment and others don't.
It is hoped their research in genome sequencing – a complete analysis of the 20,000 coding-genes which make up our personal genetic blueprint – will lead to more personalised medicine developments where a cancer is targeted with treatments based on its genetic makeup rather than a one-size-fits-all approach.
Researchers in the Centre for Cancer Biology are specialists in the field of personalised medicine and are already assisting the treatment of many South Australians with a targeted personalised medicine approach.
Researchers in the Centre for Cancer Biology are uncovering ways to prevent the metastasis of cancer cells.Read more about cell signalling research
UniSA is a leader in nanotechnology (engineering at the atomic or molecular level).
Its medical application nanomedicine is emerging as one of the key technologies of the 21st century that enables revolutionary development in cancer treatments.
Professor Clive Prestidge and his team are creating nano-structured drug delivery systems which will have numerous applications including improved and targeted drug delivery for cancer treatments.
Likewise,“lab-on-chip” devices developed by Associate Professor Benjamin Thierry's team are designed to isolate rare cancer cells in a non-invasive manner from patient's blood. These devices are so specific they can detect cancer cells present at ratios as low as 10 cancer cells per billion blood cells.
These devices promise a real breakthrough in cancer diagnostic and prognostic techniques, and are currently being tested in an ongoing clinical study at three major hospitals in the Adelaide metropolitan area.